Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Cal Gary who wrote (8347)	1/4/2002 10:50:00 AM
From: Cal Gary	Respond to of 14101

OT Monthly IMS report out. Check out Merck & Co's antifungal Caspofungin I'll have to dig further to find out what antifungal indication. But why name it caspo fung IN? I still like Wolf's FungOff. --------------- Here are the figures for sales through retail pharmacies in 13 key world markets for the 12 months to October 2001. Also, see below the latest company news briefing, summarizing December's events for the major industry players. If you don't already receive this email directly from us each month, you can register for FREE at open.imshealth.com WORLD SALES THROUGH RETAIL PHARMACIES* --------------------------------------------------------------------------- (Twelve months to October 2001) NORTH AMERICA $135.2billion, up 16% United States $129.1billion, up 16% Canada $6.1billion, up 16% EUROPE (leading 5) $53.0billion, up 9% Germany $15.0billion, up 10% France $13.7billion, up 7% Italy $9.5billion, up 12% United Kingdom $9.2billion, up 8% Spain $5.6billion, up 11% JAPAN (including hospitals) $48.3billion, up 4% LATIN AMERICA (leading 3) $13.0billion, down 3% Mexico $5.4billion, up 14% Brazil $4.3billion, down 18% Argentina $3.3billion, down 4% AUSTRALIA/NEW ZEALAND $2.9billion, up 13% More information, including sales by broad therapeutic categories for each country, is available free to download if you follow this link: open.imshealth.com Other detailed reports on pharmaceutical products, companies and therapeutic area sales are available from IMS HEALTH's online store at open.imshealth.com COMPANY NEWS IN BRIEF FOR DECEMBER --------------------------------------------------------------------- There was a flurry of M&A activity, topped by AMGEN's $16bn acquisition of IMMUNEX. The deal relegated MILLENNIUM's acquisition of COR, which followed MEDIMMUNE's deal with AVIRON and CEPHALON's purchase of LAFON. ABBOTT also took full control of VYSIS. ROCHE is taking a 50.1% stake in CHUGAI, growing its Japanese sales and re-entering the global top 10 (Chugai dissolved its joint venture with ELI LILLY). NOVO NORDISK acquired Brazil's BIOBRAS and ALPHARMA bought FAULDING's oral generics business. TANABE and TAISHO cancelled their merger, and the EC investigated BAYER's acquisition of AVENTIS' agrochemical unit. A number of alliances began, including between: AMERICAN HOME PRODUCTS and ELAN for sleeping pill Sonata; FOREST and SANKYO for antihypertensive olmesartan in the US; SANOFI-SYNTHELABO and Cephalon for tumour angiogenesis inhibitors; XENOVA and Millennium for anticancer topoisomerase inhibitors; Amgen and ISIS on antisense drugs; CHIRON and INHALE for inhaleable antibiotics; Isis and Chiron for target validation; and Roche and GLAXOSMITHKLINE for osteoporosis drug ibandronate. MERCK & CO and SCHERING-PLOUGH expanded their US anticholesterol partnership worldwide, excluding Japan. The FDA approved GSK's Paxil for post-traumatic stress; NOVARTIS' eczema cream Elidel; and AKZO NOBEL and Sanofi-Synthelabo's antithrombotic Arixtra. Canada approved ACTELION's pulmonary hypertension treatment Tracleer and SCHERING AG's Fludara for lymphoma, while the EU cleared Merck & Co's antifungal Caspofungin and LUNDBECK won the first approval for Cipralex, the follow-up to antidepressant Cipramil/Celexa, from Sweden. The FDA rejected** GSK's Augmentin XR antibiotic. Aventis and Merck & Co's hepatitis A vaccines were withdrawn in the UK over efficacy concerns, and JOHNSON & JOHNSON issued European and Canadian warnings for anaemia drug Eprex after reports of adverse effects. The FDA told BRISTOL-MYERS SQUIBB to include a liver warning for antidepressant Serzone and is seeking advice on the safety of PHARMACIA's colon cancer drug Camptosar. Merck & Co's cholesterol drug Mevacor lost US patent protection, and BARR's copy of AHP's Lo/Ovral oral contraceptive was cleared. BENTLEY's Spanish subsidiaries received approval for their generic equivalent of Schering-Plough's Claritin. The US courts were kept busy with patent litigation between Merck & Co and Barr over Fosamax; PFIZER and Barr over FemHRT; Akzo Nobel and Barr over ORGANON's Mircette oral contraceptive; Pharmacia and PAR over Xalatan; and ASTRAZENECA and a number of generic manufacturers over Prilosec. CELLTECH and GENENTECH settled their antibody patent case and GEN-PROBE and Chiron their contractual dispute. TKT was victorious in its Fabry disease litigation with GENZYME but GSK lost the first round in its Augmentin patent fight with TEVA. The investigation closed into Barr and Bayer's agreement over generic Cipro, and Pfizer's withdrawn antidiabetic Rezulin was exonerated from causing a death. BMS was sued for preventing the sale of generic BuSpar and TAP paid a $290m fine for fraudulently marketing prostate drug Lupron. Pfizer criticised France's drug pricing policy. Bayer will become a holding company with four operating subsidiaries, and AMERSHAM may abandon its biotech IPO. Lilly said the launch of two products would be delayed by manufacturing problems, while BMS and Merck & Co issued 2002 profit warnings due to patent expiries. Pfizer has no such problems - it forecast 27% earnings growth in 2001 and noted it outsells its nearest competitor by $2.4bn a year. Regards The Service Team IMS HEALTH Online Store Source: IMS HEALTH. Growth rates are calculated at a constant exchange rate, i.e. at the local currency level. The unique system in Japan reduces the importance of the pharmacy in the distribution chain - sales for Japan include hospital data. For the USA, retail, foodstore and mail order pharmacy channels are included. In other countries sales monitored are limited to retail pharmacies only. *To view this file you will need the Adobe Acrobat Reader which is free from adobe.com If you have difficulty viewing this file please reply to this message stating the exact problem you are experiencing - there are known bugs using Internet Explorer 4 and Windows NT together with pdf files. We have also been made aware of printing problems using Acrobat Reader v3.0. We recommend you use Acrobat Reader version 4 or 5. UNSUBSCRIBING If you do not wish to receive this monthly summary, you can unsubscribe at open.imshealth.com In the bottom right hand corner of the home page, type in your email address "{email}" in the space provided, and click on "Unsubscribe". Legal Stuff... Information provided by you may be collected and automatically stored on our database and may be used for sending you additional information about IMS HEALTH group services. Such information also may be transferred to IMS HEALTH companies based outside the European Union including Switzerland and the US. If you do not wish to receive further information from IMS HEALTH, please contact IMS A.G Customer Services at 7 Harewood Avenue, London, NW1 6JB, United Kingdom. service@open.imshealth.com